- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Adamis Gets Proposed Conference Presentation Approved
Adamis Pharmaceuticals announced its proposed presentation for the American Academy of Allergy, Asthma, and Immunology joint congress with the World Allergy Organization was approved.
Adamis Pharmaceuticals (NASDAQ:ADMP) announced its proposed presentation for the American Academy of Allergy, Asthma, and Immunology (AAAAI) joint congress with the World Allergy Organization was approved.
As quoted in the press release:
Dr. Dennis J. Carlo, President/CEO of Adamis stated, “Symjepi was studied in trained and untrained adults, adolescents and caregivers. The results definitively showed Symjepi to be an easy to use, small and intuitive device.” Dr. Ronald Moss, Chief Medical Officer at Adamis and a Fellow of AAAAI stated, “For a layperson, treatment of anaphylaxis with a simple non-threatening device is critical to successful use.” The presentation will focus on the successful human factors study utilizing Symjepi.
Click here to read the full press release.
Source: globenewswire.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.